PubMed · 3280665
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
D M Tatum, M Eggleston. 1988. Butoconazole nitrate.. https://doi.org/10.1086/645809
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
The aim of the present study was two-fold. First, to characterize the secretory profiles of oestradiol-17beta and progesterone in relation to the structural changes observed by ultrasonography during follicular dynamics in non-ovulating llamas. Second, to evaluate the effect of exogenous progesterone on follicular activity, in terms of follicle development and hormone production. In experiment one, six adult non-pregnant, non-lactating llamas were examined daily by rectal palpation and transrectal ultrasonography during 70 days. On day 54, intravaginal devices containing 0.33 g of progesterone (CIDR) were inserted and left in the vagina during 16 days. The mean duration of a follicular wave was 22.6+/-2.5 days. The follicular growth phase (follicles growing from 3mm to maximum size) averaged 9.2+/-2.8 days, the mature phase (follicles around maximum size) 5.2+/-1.4 days and regression phase (follicles with decreasing size) 8.2+/-2.2 days. Oestradiol-17beta plasma concentrations exhibited a similar wave pattern (P<0.05). In addition, oestradiol-17beta peak plasma concentrations (46.9+/-3.3 pmoll(-1)) were attained approximately 12 days after the beginning of the growing phase in connection with maximum follicle size (11.8+/-1.6mm). After CIDR insertion, a rapid increase in plasma progesterone concentrations was observed, with peak concentrations attained on day 1 after insertion. Thereafter, concentrations decreased gradually. Mean follicle size steadily decreased from the day of CIDR insertion to day 11 post-insertion (10.3+/-1.6 and 3.3+/-0.8mm, respectively). In order to investigate the effect of follicle size at CIDR insertion on the outcome of progesterone treatment, experiment two was designed. Sixteen adult non-pregnant and non-lactating llamas were divided into four groups according to follicle development at the time of CIDR insertion (group I: follicles < or =6 mm; group II: follicles between 6 and 9 mm; group III: follicles between 10 and 14 mm and group IV, regressing follicles). In groups II, III and IV, a significant decrease in follicle size was observed after the insertion of the CIDR device. In group I, no further development of dominant follicles was observed until the device was withdrawn. In all cases, the smallest diameter was registered between days 5 and 7 after the beginning of treatment. In conclusion, a detailed characterization of follicular waves using ultrasound and hormone determinations simultaneously in non-ovulating llamas and after the insertion of progesterone releasing devices, is presented.
Bis-cyclopentadienyl complexes of vanadium(IV) or vanadocenes are rapid and potent inhibitors of human sperm motility with potential as a new class of contraceptive agents. In this study, groups of 10 B(6)C(3)F(1) and 20 CD-1 female mice were exposed intravaginally to a gel-microemulsion containing 0, 0.06, 0.12, or 0.25% of a representative vanadocene, vanadocene acetylacetonato monotriflate (VDACAC), five days per week for 13 consecutive weeks. The doses of VDACAC used were nearly 300- to 1250-fold higher than its in vitro spermicidal EC(50) value. After 13 weeks of intravaginal treatment, B(6)C(3)F(1) mice were evaluated for survival, body weight gain, absolute and relative organ weights, and systemic toxicity. Blood was analyzed for hematological and clinical chemistry profiles. Microscopic examination was performed on hematoxylin- and eosin-stained tissue sections from each study animal. Vanadium content in tissues was determined by atomic absorption spectroscopy. Gel-microemulsion (placebo) control and VDACAC dosed female CD-1 mice were mated with untreated males in order to evaluate if VDACAC has any adverse effects on the reproductive outcome. There were no treatment-related mortalities in either study. Mean body weight gain during the dosing period was not reduced by VDACAC treatment. Hemograms or clinical chemistry profiles did not reveal any toxicologically significant changes attributed to VDACAC treatment. No clinically significant dose-dependent changes in absolute and relative organ weights were noted in VDACAC dose groups. Extensive histopathological examination of tissues revealed no treatment-related abnormalities in any of the three VDACAC dose groups. Vanadium was not incorporated in mouse tissues at levels above 1 microg/g. Repeated intravaginal exposure of CD-1 mice to increasing concentrations of VDACAC for 13 weeks had no adverse effect on their subsequent reproductive capability (100% fertile), neonatal survival (>96%) or pup development. Collectively, these findings demonstrate that repetitive intravaginal administration of VDACAC to yield effective spermicidal concentrations (<0.1%) in the vagina was not associated with systemic toxicity and did not adversely affect the reproductive performance in mice. The spermicidal vanadocene-chelated complex, VDACAC, may be useful as a safe vaginal contraceptive.
Mucosal surfaces are the primary sites for the transmission of infectious agents including viruses, so effective vaccines generally should induce mucosal immunity. Furthermore, noninvasive delivery is desirable because of the ease of application, the high degree of patient compliance, and the improved safety for patients and clinicians due to the elimination of needles. Unfortunately, most of the conventional vaccines are parenterally administered and result in systemic rather than mucosal immunity. Here we present the first report of mucosal immunity by noninvasive DNA immunization in a target species. As an approach to induce mucosal immunity against bovine herpesvirus-1, cows were immunized intravaginally with suppositories containing plasmid coding for glycoprotein D. Serum IgG, as well as IgA both in the serum and in the nasal fluids, were detected, which supports the contention of a common mucosal immune system. This level of immunity was of sufficient magnitude to minimize weight loss and significantly reduce the duration of virus shedding after intranasal viral challenge, which demonstrates the efficacy of suppository-based administration of DNA vaccines to target species. As this is a very practical method of delivery, it has great potential to be applied as vaccine or therapy in a variety of species.